Early and very early stage
hepatocellular cancers (HCC) when staged clinically, if they are coincident with histological early HCC, have the best outcome in terms of recurrence rates and survival after potential curative
therapy. This is because predictors of HCC recurrence such as microscopic vascular invasion and satellite
metastases, are rarely present in histological early HCC. Other predictors of HCC recurrence are size of the principal lesion, numbers of lesions, histological grade, several gene signature patterns that are promising for future clinical practice, and other less constantly predictive features such as high
alpha-fetoprotein and
transaminase concentrations, and cellular aneuploidia. Adjuvant and neo-adjuvant
therapies have been proposed to reduce the risk of HCC recurrence after potentially curative treatments. These preventative
therapies are focused on extra-tumoural
therapies, such as
retinoids or
interferon, possibly effective in preventing late recurrence by influencing the premalignant field in
cirrhosis, and on tumour related
therapies, by utilising several procedures able to downstage tumours, such as neo-adjuvant and "bridge to transplant"
therapies, which influence mainly early recurrence. Both strategies have been combined for example with using
sorafenib which may treat both the patient's premalignant liver and malignant liver cells themselves.